The history of the erectile dysfunction drug presents a challenging picture for investors. While the initial launch generated significant profits, the lapse of its patent opened the avenue to off-brand alternatives, https://socialevity.com/story23793944/sildenafil-and-big-pharma-a-volatile-investment